Beyond Placebo: Alternative Options to the Randomized Control Trial Design in Rare Disease Studies
DOI:
https://doi.org/10.17140/CTPOJ-3-110Keywords:
Recruitment, Enrollment, Placebo controlled, Clinical trials, Rare disease, Crossover trials, Single arm study, Historical data, n-of-1 trialsAbstract
Unique difficulties and challenges can arise for rare diseases and orphan disease indications within a clinical trial. Some of the
challenges encountered by trials that are working on rare diseases can include recruitment and enrollment. One of the explanations
for the challenges that are encountered in rare disease trials is because of the trial design of study, where the investigational
product is being compared to the placebo. This review paper discusses the usage of placebo and when other options could be
taken into consideration while creating the protocol, specifically with consideration to rare disease studies. It is essential for the
investigators and those designing the protocol to consider alternative options from the standard randomized controlled trial. The
aim of this paper is to review alternative trial design options. The trial designs discussed in this review paper include crossover
trials, single arm studies and historical data, and n-of-1 trials.
References
Augustine EF, Adams HR, Mink JW. Clinical trials in rare dis-ease: Challenges and opportunities. J Child Neurol. 2013; 28(9): 1142-1150. doi: 10.1177/0883073813495959
Gaasterland CMW, van der Weide MCJ, du Prie–Olthof MJ, et al. The patient’s view on rare disease trial design – a qualitative study. Orphanet J Rare Dis. 2019; 14: 31. doi: 10.1186/s13023-019- 1002-z
The needs of the few. Nature. 2010; 466: 160. doi: 10.1038/466160
Preethi S. Remote consent clinical research. Clin Trial Pract Open J. 2019; 1(1): 39-41. doi: 10.17140/CTPOJ-1-109
Chamberlain JM, Lillis K, Vance C, et al. Perceived challenges to obtaining informed consent for a time-sensitive emergency de-partment study of pediatric status epilepticus: Results of two focus groups. Acad Emerg Med. 2019; 16(8): 763-770. doi: 10.1111/j.1553- 2712.2009.00455.x
Portney LG, Watkins MP. Foundations of Clinical Research: Applica-tions to Practice. 3rd ed. Philadelphia, Pennsylvania: F.A. Davis Com-pany; 2015.
Day S, Jonker AH, Lau LPL, et al. Recommendations for the design of small population clinical trials. Orphanet J Rare Dis. 2018; 13: 195. doi: 10.1186/s13023-018-0931-2
Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. J Clin Epidemiol. 2011; 64(10): 1085-1094. doi: 10.1016/j. jclinepi.2010.12.019
Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: Part 18 of a series on evaluation of scientific pub-lications. Dtsch Arztebl Int. 2012; 109(15): 276-281. doi: 10.3238/ arztebl.2012.0276
Berry Consultants. Web site. https://www.youtube.com/ watch?v=ESnT3HauiD8. Accessed October 29, 2018.
Berry Consultants. Web site. https://www.youtube.com/ watch?v=ESnT3HauiD8. Accessed May 21, 2015. Submit your article to this journal | https://openventio.org/submit-manuscript/ 4 Sriram P
Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: The ultimate strategy for individualizing medicine? Per Med. 2011; 8(2): 161-173. doi: 10.2217/pme.11.7
BCH N of 1 Trial Yields Approved Therapy for Single Rare Disease Patient. Clinical OMICs. Web site. https://www.clinical-omics.com/topics/precision-medicine-topic/bch-n-of-1-trial-yields-approved-therapy-for-single-rare-disease-patient/. October 11, 2019. Mini Review | Volume 3 | Number 1 |
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Clinical Trials and Practice – Open Journal (CTP) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
